UTS2R — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL391386	0.60	20/20
Palosuran (SCHEMBL1363480)	1.00	19/20
SCHEMBL1471942	1.00	19/20
Palosuran (SCHEMBL1363165)	0.98	19/20
Palosuran (SCHEMBL1364002)	0.98	19/20
Palosuran (SCHEMBL1364658)	0.98	19/20
SCHEMBL1472012	0.82	19/20
SCHEMBL1472286	0.74	19/20
SCHEMBL1472287	0.74	19/20
SCHEMBL1472199	0.72	19/20
SCHEMBL634565	0.71	19/20
SCHEMBL634566	0.71	19/20
SCHEMBL635086	0.69	19/20
SCHEMBL635573	0.68	19/20
SCHEMBL634387	0.66	19/20
SCHEMBL634388	0.66	19/20
SCHEMBL1472274	0.62	19/20
SCHEMBL1472275	0.62	19/20
SCHEMBL1471938	1.00	18/20
SCHEMBL1472010	1.00	18/20

Clinical trials — most relevant to UTS2R by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)	PHASE4	COMPLETED
Comparative Study Between Tadalafil Versus Tamsulosin as a Medical Expulsive Therapy for Lower Ureteric Stones	PHASE4	UNKNOWN
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension	PHASE3	COMPLETED
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension	PHASE3	COMPLETED
Testosterone Effects on Pelvic Floor Muscles	PHASE3	WITHDRAWN
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus	PHASE2	UNKNOWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients	PHASE2	UNKNOWN
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma	PHASE2	COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Satiation Peptides	PHASE1	COMPLETED
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY	PHASE1	COMPLETED
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction	nan	COMPLETED
Urinary Kallikrein and Hypertension: A Prospective Study	nan	COMPLETED
Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study	nan	COMPLETED
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue	nan	RECRUITING
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)	nan	RECRUITING
The Effect of Thiazide, Amiloride and Hypertonic Saline on Urinary Biomarkers in Healthy Subjects	nan	COMPLETED
Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study	nan	COMPLETED
Detecting Bladder Cancer Using the UroMark Test.	nan	COMPLETED
Epidemiology of Gout in French Polynesia	nan	COMPLETED
Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma	nan	UNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Urine-based Detection of Non-muscle Invasive Bladder	nan	COMPLETED
Natural History of Patients With PH3 and a History of Stone Events	nan	COMPLETED
UroX Biomarker Bladder Cancer Study	nan	UNKNOWN
The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.	nan	UNKNOWN
Effect of Hypertonic Sodium Chloride on Urinary Biomarkers in Healthy Subjects and Patients With Chronic Kidney Disease	nan	COMPLETED
Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.	nan	COMPLETED
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism.	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a UTS2R binder may also engage these)

Protein	Name	Similarity
Q8HYC3	—	1.000	Q8HYC3 →
P49220	—	0.978	P49220 →
Q9JJL9	—	0.971	Q9JJL9 →
Q924U0	—	0.970	Q924U0 →
Q8VIH9	—	0.969	Q8VIH9 →
GALR3	Galanin receptor type 3	0.967	landscape →
P49684	—	0.967	P49684 →
LTB4R2	Leukotriene B4 receptor 2	0.967	landscape →
Q9BDQ5	—	0.966	Q9BDQ5 →
LTB4R	Leukotriene B4 receptor 1	0.966	landscape →
MLNR	Motilin receptor	0.965	landscape →
Q99678	—	0.962	Q99678 →
O00155	—	0.962	O00155 →
Q3T181	—	0.960	Q3T181 →
Q9JL21	—	0.959	Q9JL21 →
CCR10	C-C chemokine receptor type 10	0.958	landscape →
P30936	—	0.957	P30936 →
Q684M3	—	0.957	Q684M3 →
Q8HZN9	—	0.957	Q8HZN9 →
SSTR3	Somatostatin receptor type 3	0.957	landscape →
Q8MJV3	—	0.956	Q8MJV3 →
P0C5I1	—	0.955	P0C5I1 →
P48748	—	0.955	P48748 →
RXFP4	Relaxin-3 receptor 2	0.955	landscape →
AVPR2	Vasopressin V2 receptor	0.954	landscape →
P30935	—	0.954	P30935 →
SSTR4	Somatostatin receptor type 4	0.954	landscape →
Q9R0Q2	—	0.954	Q9R0Q2 →
O88626	—	0.953	O88626 →
Q9JKM5	—	0.953	Q9JKM5 →